Frederic Rousseau

Frederic obtained his PhD in 2001 from the University of Cambridge (UK) where he worked on mechanisms of protein folding in the laboratory of Sir Alan Fersht.

Frederic's postdoctoral work took place at the EMBL in Heidelberg (Germany) in the laboratory of Luis Serrano, where he contributed to the development of several structural modelling tools to predict mutational effect on protein stability. These tools are widely used throughout the biotech and pharmaceutical industry.

Frederic is currently a full professor and one half of a group leader duo running the SWITCH Laboratory at the KU Leuven-VIB Centre for Brain & Disease Research, (Belgium).

Frederic is a scientific founder of-, and scientific advisor to Aelin Therapuetics, a privately held Belgian biotherapeutics company that develops the therapeutic applications of the Pept-inTM technology, invented in the Switch Lab.